Open AccessInhibition of clinically significant bacterial organisms in vitro by 2-acetylpyridine thiosemicarbazones
Author(s) -
Arthur S. Dobek,
Daniel L. Klayman,
Edward T. Dickson,
John P. Scovill,
Edmund C. Tramont
Publication year - 1980
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.18.1.27
Subject(s) - microbiology and biotechnology , enterobacter , staphylococcus aureus , proteus , enterococcus , klebsiella , enterococcus faecalis , citrobacter , antibacterial activity , escherichia coli , minimum inhibitory concentration , biology , enterobacteriaceae , pseudomonas , neisseria gonorrhoeae , bacilli , shigella , antibacterial agent , pseudomonas aeruginosa , shigella flexneri , bacteria , antibiotics , biochemistry , genetics , gene
Antibacterial activity of 65 2-acetylpyridine thiosemicarbazones and related compounds was determined by using clinical isolates of nine bacterial genera. Minimal inhibitory concentrations (MICs) of 0.002 to 0.062 micrograms/ml were obtained with 23% of the compounds for Neisseria gonorrhoeae and 0.016 to 0.062 micrograms/ml with 17% of the compounds for N. meningitidis. Staphylococcus aureus was inhibited in the MIC range of 0.125 to 0.5 micrograms/ml by 18% of the thiosemicarbazones, whereas 26% inhibited group D enterococcus with an MIC of 0.25 to 2.0 micrograms/ml. Poor antibacterial activity was shown toward the gram-negative bacilli, i.e., Pseudomonas, Klebsiella-Enterobacter, Shigella, Escherichia coli, and Proteus.